Alina Sami Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alina Sami Khan has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Mahima Khatri
Medicine and Surgery, Dow University of Health Sciences, Karachi, Karachi, PAK
4 shared publicationsSatesh Kumar
Medicine and Surgery, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, PAK
4 shared publicationsAlina A Muhammad
Medicine and Surgery, Liaquat National Hospital and Medical College, Karachi, PAK
2 shared publicationsArham Iqbal
Medicine and Surgery, Dow University of Health Sciences, Dow International Medical College, Karachi, PAK
2 shared publicationsFariha Mazhar
Medicine and Surgery, Liaquat National Hospital and Medical College, Karachi, PAK
2 shared publicationsGiustino Varrassi
Pain Medicine, Paolo Procacci Foundation, Rome, ITA
2 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 86
Next generation microbiome therapeutics in gastrointestinal disease: from fecal microbiota transplantation to engineered consortia — a narrative review
The human intestine contains trillions of microorganisms which form an ecosystem that is responsible for regulating gastrointestinal (GI) health. The collection of bacteria, viruses, fungi, and their genes constitutes the microbiome. Dysbiosis, or imbalance of the microbial system, has been linked to diseases such as recurrent Clostridioides difficile infection (rCDI), inflammatory bowel disease (IBD), and colorectal cancer (CRC). Although fecal microbiota transplantation (FMT) has been indicated for safe use in rCDI, reoccurrence remains common. Similarly, in IBD, FMT has shown limited ability to induce clinical remission in patients. Newer strategies for microbial restoration have since emerged, with live biotherapeutic products (LBPs) first defined by the U.S. Food and Drug Administration (FDA) in 2012, and engineered microbial consortia, gaining prominence in the early 2000s. Although FMT remains the main therapy for rCDI, its variable donor compositions and concern for safety have encouraged development of more refined options for microbial restoration. This review will comprehensively examine LBPs such as RBX2660 (Rebyota) and SER-109 (Vowst), in addition to investigational consortia such as VE303, CP101, and MET-2. It also explores their clinical applications, advantages, medical complications, regulatory compliance, and future directions of these microbial therapies.
- 10 July 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 86
Open AccessNext generation microbiome therapeutics in gastrointestinal disease: from fecal microbiota transplantation to engineered consortia — a narrative review
The human intestine contains trillions of microorganisms which form an ecosystem that is responsible for regulating gastrointestinal (GI) health. The collection of bacteria, viruses, fungi, and their genes constitutes the microbiome. Dysbiosis, or imbalance of the microbial system, has been linked to diseases such as recurrent Clostridioides difficile infection (rCDI), inflammatory bowel disease (IBD), and colorectal cancer (CRC). Although fecal microbiota transplantation (FMT) has been indicated for safe use in rCDI, reoccurrence remains common. Similarly, in IBD, FMT has shown limited ability to induce clinical remission in patients. Newer strategies for microbial restoration have since emerged, with live biotherapeutic products (LBPs) first defined by the U.S. Food and Drug Administration (FDA) in 2012, and engineered microbial consortia, gaining prominence in the early 2000s. Although FMT remains the main therapy for rCDI, its variable donor compositions and concern for safety have encouraged development of more refined options for microbial restoration. This review will comprehensively examine LBPs such as RBX2660 (Rebyota) and SER-109 (Vowst), in addition to investigational consortia such as VE303, CP101, and MET-2. It also explores their clinical applications, advantages, medical complications, regulatory compliance, and future directions of these microbial therapies.
- Open Access
- 23 September 2025
- Published by Springer Nature in Cureus
- Vol. 15 (4) , c305
Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
This article has been corrected to fix the following typos in the PRISMA diagram: Records removed before screening corrected from 2,125 to 1,425 Reports excluded due to "full text not available, retraction, or erroneous indexing" corrected from 0 to 10
- 23 September 2025
- Published by Springer Nature in Cureus
- Vol. 15 (4) , c305
Open AccessSafety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
This article has been corrected to fix the following typos in the PRISMA diagram: Records removed before screening corrected from 2,125 to 1,425 Reports excluded due to "full text not available, retraction, or erroneous indexing" corrected from 0 to 10
- Open Access
- 1 July 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (7) , 6355-6373
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Valve Replacement: An Umbrella Review
Atrial fibrillation (AF) is a major sequela after bioprosthetic valve replacement (BPVR) in patients with valvular heart disease. This study evaluates the data compiled from different meta-analyses in an umbrella review. We investigated the anticoagulation efficacy of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with AF and BPVR. A comprehensive search of the Cochrane Database of Systematic Reviews, EMBASE, and PubMed was completed to find papers published up until June 2024 that could be included in this umbrella review. Randomized controlled trials (RCTs) and retrospective observational/cohort studies were primarily identified as the foundation of meta-analyses and peer-reviewed systematic reviews. The quality of the included publications was determined using the AMSTAR 2 tool and the Cochrane Collaboration’s risk-of-bias tool, while the overall certainty of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. A total of 20 systematic reviews and meta-analyses of RCTs and observational studies were included in this umbrella review. Among the primary outcomes, the pooled analysis exhibited a significant reduction in all-cause mortality (risk ratio [RR], 0.95; 95% confidence interval [CI], 0.91–1.00; P = .05; I2 = 0%), risk of major/life-threatening bleeding (RR, 0.73; 95% CI, 0.66–0.82; P ≤ .00001; I2 = 66%), and stroke/thromboembolism (RR, 0.74; 95% CI, 0.67–0.82; P = .00001; I2 = 0%) in patients who were administered DOAC pharmacotherapy as compared to VKAs. The only primary outcome that demonstrated clinically insignificant results was all-cause stroke (RR, 0.9; 95% CI, 0.79–1.04; P = .16; I2 = 54%). Secondary outcomes such as intracranial bleeding, any bleeding, and minor or clinically insignificant bleeding all showed a significantly decreased risk in the DOAC group versus the VKA group. Only two outcomes revealed an increased risk of cardiovascular events and risk of ischemic stroke in patients who received DOACs; however, these outcomes were statistically insignificant. According to our analysis, DOACs exhibit a superior safety and efficacy profile to that of VKAs when it comes to treating patients with BPVR. DOACs do not require continuous monitoring; therefore, they could be an effective substitute for VKAs in these individuals.
- 1 July 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (7) , 6355-6373
Open AccessDirect Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Valve Replacement: An Umbrella Review
Atrial fibrillation (AF) is a major sequela after bioprosthetic valve replacement (BPVR) in patients with valvular heart disease. This study evaluates the data compiled from different meta-analyses in an umbrella review. We investigated the anticoagulation efficacy of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with AF and BPVR. A comprehensive search of the Cochrane Database of Systematic Reviews, EMBASE, and PubMed was completed to find papers published up until June 2024 that could be included in this umbrella review. Randomized controlled trials (RCTs) and retrospective observational/cohort studies were primarily identified as the foundation of meta-analyses and peer-reviewed systematic reviews. The quality of the included publications was determined using the AMSTAR 2 tool and the Cochrane Collaboration’s risk-of-bias tool, while the overall certainty of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. A total of 20 systematic reviews and meta-analyses of RCTs and observational studies were included in this umbrella review. Among the primary outcomes, the pooled analysis exhibited a significant reduction in all-cause mortality (risk ratio [RR], 0.95; 95% confidence interval [CI], 0.91–1.00; P = .05; I2 = 0%), risk of major/life-threatening bleeding (RR, 0.73; 95% CI, 0.66–0.82; P ≤ .00001; I2 = 66%), and stroke/thromboembolism (RR, 0.74; 95% CI, 0.67–0.82; P = .00001; I2 = 0%) in patients who were administered DOAC pharmacotherapy as compared to VKAs. The only primary outcome that demonstrated clinically insignificant results was all-cause stroke (RR, 0.9; 95% CI, 0.79–1.04; P = .16; I2 = 54%). Secondary outcomes such as intracranial bleeding, any bleeding, and minor or clinically insignificant bleeding all showed a significantly decreased risk in the DOAC group versus the VKA group. Only two outcomes revealed an increased risk of cardiovascular events and risk of ischemic stroke in patients who received DOACs; however, these outcomes were statistically insignificant. According to our analysis, DOACs exhibit a superior safety and efficacy profile to that of VKAs when it comes to treating patients with BPVR. DOACs do not require continuous monitoring; therefore, they could be an effective substitute for VKAs in these individuals.
- Open Access
- 1 June 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (6) , 6307-6328
Comparison Between Efficacy and Safety of Remote Magnetic Navigation and Manual Catheter Navigation for Atrial Fibrillation Ablation: An Updated Meta-analysis and Systematic Review
Comparison Between Efficacy and Safety of Remote Magnetic Navigation and Manual Catheter Navigation for Atrial Fibrillation Ablation: An Updated Meta-analysis and Systematic Review
- 1 June 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (6) , 6307-6328
Open AccessComparison Between Efficacy and Safety of Remote Magnetic Navigation and Manual Catheter Navigation for Atrial Fibrillation Ablation: An Updated Meta-analysis and Systematic Review
Comparison Between Efficacy and Safety of Remote Magnetic Navigation and Manual Catheter Navigation for Atrial Fibrillation Ablation: An Updated Meta-analysis and Systematic Review
- Open Access
- 27 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2149-2162
Influence of gut microbiota on the pediatric endocrine system and associated disorders
The microbiota, a complex assembly of microorganisms residing in various body systems, including the gastrointestinal tract, plays a crucial role in influencing various physiological processes in the human body. The dynamic nature of gut microbiota is especially pronounced in children and is influenced by factors like breastfeeding and antibiotic use. Dysbiosis, characterized by alterations in microbiota composition or function, is associated with several pediatric endocrine disorders, such as precocious puberty, polycystic ovarian syndrome, and diabetes mellitus. This review focuses on the intricate relationship between gut microbiota and the pediatric endocrine system. The aim of this narrative review is to critically examine the existing literature to elucidate the impact of gut microbiota on the pediatric endocrine system and associated disorders. Additionally, potential interventions, such as probiotics and current gaps in knowledge, will be discussed. Despite emerging treatments like probiotics, further research is needed to understand and validate their effectiveness in treating pediatric endocrine disorders associated with dysbiosis.
- 27 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2149-2162
Open AccessInfluence of gut microbiota on the pediatric endocrine system and associated disorders
The microbiota, a complex assembly of microorganisms residing in various body systems, including the gastrointestinal tract, plays a crucial role in influencing various physiological processes in the human body. The dynamic nature of gut microbiota is especially pronounced in children and is influenced by factors like breastfeeding and antibiotic use. Dysbiosis, characterized by alterations in microbiota composition or function, is associated with several pediatric endocrine disorders, such as precocious puberty, polycystic ovarian syndrome, and diabetes mellitus. This review focuses on the intricate relationship between gut microbiota and the pediatric endocrine system. The aim of this narrative review is to critically examine the existing literature to elucidate the impact of gut microbiota on the pediatric endocrine system and associated disorders. Additionally, potential interventions, such as probiotics and current gaps in knowledge, will be discussed. Despite emerging treatments like probiotics, further research is needed to understand and validate their effectiveness in treating pediatric endocrine disorders associated with dysbiosis.
- 8 August 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 202, 104471
Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy
- 8 August 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 202, 104471
Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy
- Open Access
- 16 April 2023
- Published by Springer Nature in Cureus
- Vol. 15 (4) , e37650
Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
Community-acquired pneumonia is a leading cause of morbidity and mortality throughout the world, which incurs significant healthcare costs. The aim of his meta-analysis is to assess the clinical efficacy and safety of a novel non-fluorinated quinolone, nemonoxacin, compared with levofloxacin in treating community-acquired pneumonia (CAP). A recursive literature search was conducted using PubMed, Google Scholar, and Scopus up to August 2022. All randomized clinical trials comparing nemonoxacin to levofloxacin for community-acquired pneumonia were included. The patients selected for this study had mild to moderate CAP. Each individual received treatment with either nemonoxacin (500 mg or 750 mg) or levofloxacin (500 mg) for a duration of 3-10 days. Four randomized control trials with a total of 1955 patients were included. Nemonoxacin and levofloxacin were found to have similar clinical cure rates in the treatment of CAP. There were no significant differences reported in the treatment-emergent adverse events between the two drugs (RR=0.95, 95% CI: 0.86, 1.08, I2=0%). However, the most frequent symptoms exhibited were gastrointestinal system-related. Both the dosages (500 mg and 750 mg) of nemonoxacin were found to have similar efficacy as that of levofloxacin. Our meta-analysis indicates that nemonoxacin is a well-tolerated and effective antibiotic therapy for the treatment of community-acquired pneumonia (CAP), with clinical success rates comparable to those of levofloxacin. Furthermore, the adverse effects associated with nemonoxacin are generally mild. Therefore, both the 500 mg and 750 mg dosages of nemonoxacin can be recommended as appropriate antibiotic therapy regimens for the treatment of CAP.
- 16 April 2023
- Published by Springer Nature in Cureus
- Vol. 15 (4) , e37650
Open AccessSafety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
Community-acquired pneumonia is a leading cause of morbidity and mortality throughout the world, which incurs significant healthcare costs. The aim of his meta-analysis is to assess the clinical efficacy and safety of a novel non-fluorinated quinolone, nemonoxacin, compared with levofloxacin in treating community-acquired pneumonia (CAP). A recursive literature search was conducted using PubMed, Google Scholar, and Scopus up to August 2022. All randomized clinical trials comparing nemonoxacin to levofloxacin for community-acquired pneumonia were included. The patients selected for this study had mild to moderate CAP. Each individual received treatment with either nemonoxacin (500 mg or 750 mg) or levofloxacin (500 mg) for a duration of 3-10 days. Four randomized control trials with a total of 1955 patients were included. Nemonoxacin and levofloxacin were found to have similar clinical cure rates in the treatment of CAP. There were no significant differences reported in the treatment-emergent adverse events between the two drugs (RR=0.95, 95% CI: 0.86, 1.08, I2=0%). However, the most frequent symptoms exhibited were gastrointestinal system-related. Both the dosages (500 mg and 750 mg) of nemonoxacin were found to have similar efficacy as that of levofloxacin. Our meta-analysis indicates that nemonoxacin is a well-tolerated and effective antibiotic therapy for the treatment of community-acquired pneumonia (CAP), with clinical success rates comparable to those of levofloxacin. Furthermore, the adverse effects associated with nemonoxacin are generally mild. Therefore, both the 500 mg and 750 mg dosages of nemonoxacin can be recommended as appropriate antibiotic therapy regimens for the treatment of CAP.
- 2 October 2022
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 37 (12) , 5693-5694
Letter to the editor: Preoperative evaluation of aortic calcification by computed tomography in thoracic aortic disease
- 2 October 2022
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 37 (12) , 5693-5694
Letter to the editor: Preoperative evaluation of aortic calcification by computed tomography in thoracic aortic disease